Amanta Healthcare Ltd

Amanta Healthcare Ltd’s share price declined to a fresh 52-week low of Rs 93.1 on 23 March 2026, marking a significant milestone in the stock’s recent performance amid broader market weakness and sectoral pressures.

Despite a broader market rally, Amanta Healthcare Ltd has plunged to a fresh 52-week low of Rs 93.1 on 23 Mar 2026, marking a significant divergence from sector and index trends.

Amanta Healthcare Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 22 December 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 21 March 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Shares of Amanta Healthcare Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, declined to a fresh all-time low of Rs.93.25 on 12 Mar 2026, marking a significant milestone in the stock’s downward trajectory. This new 52-week low reflects ongoing pressures despite some positive quarterly financial indicators, with the stock underperforming its sector and broader market indices over multiple time frames.

Shares of Amanta Healthcare Ltd touched a new 52-week low today, closing at Rs 93.25, marking a significant decline amid broader market weakness and company-specific factors.

Amanta Healthcare Ltd’s stock declined sharply to a new 52-week low of Rs.94.05 on 11 Mar 2026, marking a significant drop amid broader sector and market pressures. The stock has underperformed its Pharmaceuticals & Biotechnology sector peers and the broader Sensex index, reflecting ongoing concerns about its financial trajectory and market positioning.

Amanta Healthcare Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 22 December 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 10 March 2026, providing investors with an up-to-date perspective on the company’s fundamentals, valuation, financial trends, and technical outlook.

Amanta Healthcare Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 22 December 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 25 February 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Amanta Healthcare Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 22 December 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 14 February 2026, providing investors with the latest insights into the company’s fundamentals, valuation, financial trends, and technical outlook.

Amanta Healthcare Ltd has demonstrated a notable turnaround in its financial performance for the quarter ended December 2025, shifting from a flat to a positive growth trajectory. This improvement is reflected in key metrics such as revenue, profitability, and operating efficiency, signalling a potential stabilisation in the company’s business fundamentals despite broader market headwinds.

Amanta Healthcare Ltd. reported a robust 282.64% quarter-on-quarter surge in net profit for Q3 FY26, reaching ₹4.63 crores compared to ₹1.21 crores in Q2 FY26, whilst also posting a modest 8.15% year-on-year growth from ₹4.28 crores in Q3 FY25. The micro-cap pharmaceutical company, with a market capitalisation of ₹413 crores, saw its stock trade at ₹107.75 on February 10, 2026, up 1.51% from the previous close. However, beneath the headline profit growth lies a complex narrative of margin compression and operational challenges that warrant closer scrutiny from investors.

Amanta Healthcare Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 22 December 2025. However, the analysis and financial metrics discussed below reflect the stock's current position as of 03 February 2026, providing investors with an up-to-date perspective on the company’s fundamentals, valuation, financial trends, and technical outlook.

Amanta Healthcar is rated 'Sell' by MarketsMOJO, with this rating last updated on 22 December 2025. However, the analysis and financial metrics presented here reflect the stock's current position as of 23 January 2026, providing investors with an up-to-date view of the company's fundamentals, valuation, financial trends, and technical outlook.

Amanta Healthcar is rated 'Sell' by MarketsMOJO, with this rating last updated on 22 December 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 12 January 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Amanta Healthcar is rated 'Sell' by MarketsMOJO, with this rating last updated on 22 December 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 29 December 2025, providing investors with the latest insights into the company’s performance and outlook.

Amanta Healthcare’s recent market assessment reflects a nuanced picture shaped by its financial performance, valuation metrics, and technical indicators. The pharmaceutical company’s long-term sales trajectory, debt servicing capacity, and return ratios have influenced a revision in its evaluation, highlighting both challenges and areas of relative strength within a competitive sector.